[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,79,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100643230","flow-based-platelet-function-assessment-using-total-thrombus-formation-analysis-system-t-tas-and-early-bleeding-after-cardiac-surgery-with-cardiopulmonary-bypass-cpb-100643230",false,"NCT07619261","Flow-Based Platelet Function Assessment Using Total Thrombus-Formation Analysis System (T-TAS) and Early Bleeding After Cardiac Surgery With Cardiopulmonary Bypass (CPB)","Prospective Observational Study of Flow-Based Platelet Function Using T-TAS and Early Bleeding After Cardiopulmonary Bypass in Adult Cardiac Surgery","TTAS-CPB","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Undergoing elective or urgent cardiac surgery requiring cardiopulmonary bypass\n3. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Cardiac surgery performed without cardiopulmonary bypass\n2. Emergency cardiac surgery\n3. Preoperative anticoagulation not reversed at the time of surgery\n4. Refusal or withdrawal of informed consent\n5. Known pregnancy","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","2 Days","OBSERVATIONAL","The goal of this observational study is to learn how flow-based platelet function measured with the Total Thrombus-formation Analysis System (T-TAS) relates to early postoperative bleeding in adults undergoing cardiac surgery with cardiopulmonary bypass. The study will also evaluate how T-TAS changes during the perioperative period and how it compares with standard coagulation and platelet function tests.\n\nThe main questions it aims to answer are:\n\nIs lower post-cardiopulmonary bypass T-TAS Platelet-chip (PL-chip) thrombus formation associated with increased postoperative chest tube drainage during the first 12 hours after surgery? How do T-TAS parameters change before surgery, immediately after cardiopulmonary bypass, and 24 hours after surgery? Are abnormal T-TAS results associated with blood transfusion requirements, major bleeding, re-exploration for bleeding, and length of stay in the intensive care unit and hospital? Does T-TAS provide complementary information compared with standard coagulation tests, von Willebrand factor (vWF) measurements, platelet aggregometry, and viscoelastic testing?\n\nParticipants will:\n\nUndergo blood sampling at three predefined perioperative time points:\n\nbefore anesthesia induction, immediately after cardiopulmonary bypass and heparin reversal with protamine, and 24 hours after surgery Have T-TAS testing, standard laboratory coagulation tests, vWF testing, platelet aggregometry, and viscoelastic testing performed on collected samples Have clinical, surgical, transfusion, and postoperative bleeding data collected during their hospital stay\n\nThe study is observational and does not require changes to routine clinical care or perioperative management.",[26,27,28,29,30],"Perioperative Bleeding","Coagulopathy During Cardiac Surgery","Platelet Dysfunction","Cardiac Surgery","Acquired Von Willebrand Disease",[29,32,33,34,35,36,37,38,39,40],"Total Thrombus formation Analysis System (T-TAS)","Platelet Function","Postoperative Bleeding","Hemostasis","Blood Transfusion","ROTEM","Thrombus Formation","Cardiopulmonary Bypass (CPB)","von Willebrand Factor (vWF)","NOT_YET_RECRUITING","2026-06-08",{"date":44,"type":45},"2026-06-10","ACTUAL",{"date":47,"type":21},"2026-09-15",{"date":49,"type":21},"2027-02-15",{"name":51,"class":52},"Hospital de la Santa creu i Sant Pau - Barcelona","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100547249","platelet-function-after-cardiac-surgery-100547249","NCT06405516","Platelet Function After Cardiac Surgery.","Platelet Count and Function After Usage of Two Different Cell Saver Devices During Cardiac Surgery: a Randomized Controlled Multi-center Equivalence Trial.","PLFICS","Inclusion Criteria:\n\n* Age \\>18 years\n* Elective high risk cardiac surgery with cardiopulmonary bypass usage\n* Cardiopulmonary bypass time \\> 120 minutes\n* Written informed consent\n\nExclusion Criteria:\n\n* Preoperative use of oral or intravenous anti-coagulants or antiplatelet agents (except aspirin)\n* Inability to understand and sign the informed consent form (e.g. language problems, dementia, mental disorders).",{"count":62,"type":21},40,"INTERVENTIONAL",[65],"NA","Intraoperative cell salvage is commonly used in cardiac surgery to reduce the administration of allogeneic red blood cells and thus improve the outcome for the patient. When processing the salvaged blood, however, a large part of the patient's plasma is washed out. This is a disadvantage with regard to an optimal coagulation situation after cardiac surgery.\n\nThere are currently various cell saver systems on the market. According to the manufacturers, the plasma is returned to the patient in different quantities as part of the processing procedure. Thus, it can be assumed that in addition to red blood cells, platelets (part of plasma) are retransfused and contribute to an optimized coagulation. Unfortunately, there is a lack of studies in this regard in the cardiac surgery population.\n\nThe investigators aim to study the performance of two different cell saver devices regarding preservation of platelet number and function.",[28],"RECRUITING","2025-06-03",{"date":71,"type":45},"2025-06-06",{"date":73,"type":45},"2024-06-12",{"date":75,"type":21},"2026-01-01",{"name":77,"class":52},"Insel Gruppe AG, University Hospital Bern",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":63,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":78},"100577003","phase-2-cangrelor-on-top-of-anticoagulation-in-patients-with-myocardial-infarction-related-cardiogenic-shockcardiac-arrest-receiving-va-ecmo-100577003","NCT06792643","Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock\u002FCardiac Arrest receiVIng VA-ECMO","Efficacy and Safety of Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction Related Cardiogenic Shock\u002FCardiac Arrest receiVIng VAECMO Support - a Phase 2, Single Arm, Single Center Trial","SURVIVE","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years;\n* ACS-related CS\u002FCA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;\n* Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;\n* Written informed consent\n\nExclusion Criteria:\n\n* Overt uncontrollable bleeding;\n* Suspected intra-cranial haemorrhage;\n* Patients who received any dose of any oral P2Y12-inhibitors;\n* Patients with known history of stroke or Transient Ischaemic Attack (TIA);\n* Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;\n* Pregnancy.",{"count":88,"type":21},50,[90],"PHASE2","The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)\u002F cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.",[93,94,28],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation Complication",[96,97,93,98,99,100,101,102,103,104],"Cangrelor","ACS","PCI","ECMO","VA-EMO","Acute coronary syndrome","P2Y12","Anti-thrombotic therapy","Extracorporeal Membrane Oxygenation","2025-01-21",{"date":107,"type":45},"2025-01-27",{"date":109,"type":45},"2024-04-01",{"date":111,"type":21},"2025-12-31",{"name":113,"class":52},"IRCCS San Raffaele",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":121,"targetDuration":123,"studyType":23,"phases":4,"briefSummary":124,"conditions":125,"keywords":141,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100572008","longitudinal-cohort-of-thrombosis-and-hemostasis-diseases-100572008","NCT06727669","Longitudinal Cohort of Thrombosis and Hemostasis Diseases","Inclusion Criteria:\n\n* Patients who were diagnosed as thrombosis and hemostasis diseases.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",true,{"count":122,"type":21},3000,"5 Years","This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.",[126,127,128,129,130,131,132,133,134,135,136,137,28,138,139,140],"Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura","Hemophilia A, Acquired","Disseminated Intravascular Coagulation","Thrombophilia","Deep Vein Thrombosis","Pulmonary Embolism","Thrombotic Microangiopathies","Coagulation Factor Deficiency","Hemophilia A","Hemophilia B","Hemophilia B, Acquired","Arterial Thromboembolism","Bleeding Disorder","Thrombosis",[140,35],"2024-12-05",{"date":144,"type":45},"2024-12-11",{"date":146,"type":45},"2024-11-01",{"date":148,"type":21},"2030-12-31",{"name":150,"class":52},"Peking University People's Hospital",5]